LOPRESSOR
LOE ApproachingNDAORALTABLET, EXTENDED RELEASE
Approved
Dec 1989
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
LOPRESSOR by Novartis is 12. Approved for the treatment of hemodynamically stable adult patients with myocardial infarction, to reduce the risk of cardiovascular mortality, the treatment of hemodynamically stable adult patients with myocardial infarction (mi) to reduce cardiovascular mortality. First approved in 1989.
Drug data last refreshed 10h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LOPRESSOR (metoprolol) is a beta-1 selective (cardioselective) adrenergic receptor blocking agent indicated for reducing cardiovascular mortality in hemodynamically stable adult patients following myocardial infarction. It works by slowing heart rate and decreasing AV nodal conduction, with preferential beta-1 selectivity that spares beta-2 receptors at therapeutic doses.
LOE Approaching
As LOE approaches, the brand team is likely consolidating and shifting focus to generic transition planning and lifecycle management initiatives.
Mechanism of Action
12.1 Mechanism of Action Metoprolol is a beta 1 -selective (cardioselective) adrenergic receptor blocking agent. This preferential effect is not absolute, however, and at higher plasma concentrations, metoprolol also inhibits beta 2 -adrenoreceptors, chiefly located in the bronchial and vascular…
Worked on LOPRESSOR at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.